Back to Browse Journals » Drug Design, Development and Therapy » Volume 5

Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel

Authors Andrew S Bomback, James A Tumlin, Joel Baranski, et al

Published Date March 2011 Volume 2011:5 Pages 147—153


Published 14 March 2011

Andrew S Bomback1, James A Tumlin2, Joel Baranski3, James E Bourdeau4, Anatole Besarab5, Alice S Appel1, Jai Radhakrishnan1, Gerald B Appel1
1Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, NY, USA; 2Department of Internal Medicine, Division of Nephrology, University of Tennessee College of Medicine in Chattanooga, Chattanooga, TN, USA; 3Balboa Nephrology Medical Group, San Diego, CA, USA; 4Nephrology Specialists of Oklahoma, Tulsa, OK, USA; 5Department of Medicine, Division of Nephrology and Hypertension, Henry Ford Health System, Detroit, MI, USA

Purpose: A synthetic adrenocorticotropin (ACTH) analog has shown efficacy in Europe as primary and secondary therapy for nephrotic syndrome, but there is no published experience using the natural, highly purified ACTH gel formulation, available in the United States, for nephrotic syndrome. We therefore investigated the use of ACTH gel for nephrotic syndrome in the United States.
Patients and methods: Twenty-one patients with nephrotic syndrome treated with ACTH gel outside of research settings in the United States, with initiation of therapy by December 31, 2009, allowing a minimum 6 months follow-up. We defined complete remission as stable renal function with proteinuria falling to <500 mg/day, and partial remission as stable renal function with >50% reduction in proteinuria from 500 to 3500 mg/day.
Results: Twenty-one patients with nephrotic syndrome were treated: 11 with idiopathic membranous nephropathy (iMN), 4 with membranoproliferative glomerulonephritis (MPGN), 1 with focal segmental glomerulosclerosis (FSGS), 1 with minimal change disease (MCD), 1 with immunoglobulin A (IgA) nephropathy, 1 with class V systemic lupus erythematosus (SLE) glomerulonephritis, 1 with monoclonal diffuse proliferative glomerulonephritis, and 1 with unbiopsied nephrotic syndrome. ACTH was used as primary therapy for 3 patients; the remaining patients had previously failed a mean 2.3 immunosuppressive regimens. Eleven patients achieved a complete or partial remission, with 4 (19%) in complete remission. Of the 11 patients who achieved remission, 9 had iMN, 1 had FSGS, and 1 had IgA nephropathy. Of the 11 patients with iMN, 3 (27%) achieved complete remission and 6 (55%) achieved partial remission despite having previously failed a mean 2.4 therapies. Five patients reported steroid-like adverse effects, but there were no severe infections. The limitations were retrospective data analysis with short-term follow-up.
Conclusion: ACTH gel may be a viable treatment option for resistant nephrotic syndrome due to membranous nephropathy. Short-term data suggest that remission rates may approach 80%.

Keywords: nephrotic syndrome, membranous nephropathy, chronic kidney disease

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Current and novel drug therapies for idiopathic pulmonary fibrosis

Adamali HI, Maher TM

Drug Design, Development and Therapy 2012, 6:261-272

Published Date: 26 September 2012

Development of oral immunomodulatory agents in the management of multiple sclerosis

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA

Drug Design, Development and Therapy 2011, 5:255-274

Published Date: 10 May 2011

Adherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorder

Xianchen Liu, Yi Chen, Douglas E Faries, et al

ClinicoEconomics and Outcomes Research 2011, 3:63-72

Published Date: 15 March 2011

Continuation treatment of major depressive disorder: is there a case for duloxetine?

Trevor R Norman, James S Olver

Drug Design, Development and Therapy 2010, 4:19-31

Published Date: 12 February 2010

Duloxetine for the management of fibromyalgia syndrome

Beth A Scholz, Cara L Hammonds, Chad S Boomershine

Journal of Pain Research 2009, 2:99-108

Published Date: 21 July 2009

Structure-based design of anticancer prodrug PABA/NO

Xinhua Ji, Ajai Pal, Ravi Kalathur, Xun Hu, Yijun Gu, et al

Drug Design, Development and Therapy 2008, 2:123-130

Published Date: 11 August 2008

Modafinil in the treatment of excessive sleepiness

Jonathan RL Schwartz

Drug Design, Development and Therapy 2008, 2:71-85

Published Date: 20 May 2008